Drug discovery and development focusing on existing medicines: Drug re-profiling strategy

Tohru Mizushima

研究成果: Review article査読

26 被引用数 (Scopus)

抄録

As a new strategy for drug discovery and development, I focus on drug re-profiling as a way to identify new treatments for diseases. In this strategy, the actions of existing medicines, whose safety and pharmacokinetic effects in humans have already been confirmed clinically and approved for use, are examined comprehensively at the molecular level and the results used for the development of new medicines. This strategy is based on the fact that we still do not understand the underlying mechanisms of action of many existing medicines, and as such the cellular responses that give rise to their main effects and side effects are yet to be elucidated. To this extent, identification of the mechanisms underlying the side effects of medicines offers a means for us to develop safer drugs. The results can also be used for developing existing drugs for use as medicines for the treatment of other diseases. Promoting this research strategy could provide breakthroughs in drug discovery and development. The Authors 2011. Published by Oxford University Press on behalf of the Japanese Biochemical Society. All rights reserved2011

本文言語English
ページ(範囲)499-505
ページ数7
ジャーナルJournal of biochemistry
149
5
DOI
出版ステータスPublished - 2011 5
外部発表はい

ASJC Scopus subject areas

  • 生化学
  • 分子生物学

フィンガープリント

「Drug discovery and development focusing on existing medicines: Drug re-profiling strategy」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル